Insider Selling: Jazz Pharmaceuticals PLC (JAZZ) CFO Sells 700 Shares of Stock

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CFO Matthew P. Young sold 700 shares of the business’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $158.08, for a total transaction of $110,656.00. Following the completion of the sale, the chief financial officer now directly owns 32,768 shares of the company’s stock, valued at approximately $5,179,965.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals stock traded up $3.38 during mid-day trading on Friday, reaching $145.57. The stock had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. Jazz Pharmaceuticals PLC has a one year low of $130.15 and a one year high of $184.00. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.29 and a quick ratio of 3.62. The stock has a market cap of $8.47 billion, a price-to-earnings ratio of 15.23, a PEG ratio of 0.76 and a beta of 1.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.32 by $0.26. The firm had revenue of $469.37 million during the quarter, compared to analyst estimates of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.22 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 11.71 EPS for the current fiscal year.

JAZZ has been the subject of several recent research reports. Evercore ISI restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Friday, July 13th. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. BidaskClub lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $203.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $191.94.

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in Jazz Pharmaceuticals by 113.7% in the second quarter. Russell Investments Group Ltd. now owns 68,430 shares of the specialty pharmaceutical company’s stock worth $11,798,000 after acquiring an additional 36,415 shares in the last quarter. Legal & General Group Plc raised its position in Jazz Pharmaceuticals by 1.8% during the second quarter. Legal & General Group Plc now owns 241,295 shares of the specialty pharmaceutical company’s stock valued at $41,575,000 after acquiring an additional 4,268 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Jazz Pharmaceuticals by 19.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 260,768 shares of the specialty pharmaceutical company’s stock valued at $44,931,000 after acquiring an additional 42,463 shares in the last quarter. LPL Financial LLC raised its position in Jazz Pharmaceuticals by 27.7% during the first quarter. LPL Financial LLC now owns 4,801 shares of the specialty pharmaceutical company’s stock valued at $725,000 after acquiring an additional 1,041 shares in the last quarter. Finally, Castleark Management LLC increased its position in shares of Jazz Pharmaceuticals by 31.9% in the second quarter. Castleark Management LLC now owns 43,795 shares of the specialty pharmaceutical company’s stock valued at $7,546,000 after buying an additional 10,595 shares in the last quarter. 92.95% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Jazz Pharmaceuticals PLC (JAZZ) CFO Sells 700 Shares of Stock” was originally reported by Equities Focus and is owned by of Equities Focus. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.equitiesfocus.com/2018/11/10/matthew-p-young-sells-700-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: Penny Stocks, Risk and Reward Factors

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply